Introduction A high frequency of β‐thalassemia in Lao People's Democratic Republic necessitates the importance of complete molecular data before a prevention and control program could be established. Limited data are available for Lao PDR. We have now reported an extended information on the molecular basis of β‐hemoglobinopathies in this population. Methods The study was done on 519 unrelated Laos subjects requested for thalassemia investigation. Hematological data were recorded. Hb profiles were obtained using a capillary electrophoresis system. α‐And β‐globin genotyping was performed using PCR and related techniques. Results Among the 519 subjects, 287 (55.3%) were found to carry β‐hemoglobinopathies based on Hb and DNA analyses. These included Hb E carriers (n = 135), homozygous Hb E (n = 47), β‐thalassemia carriers (n = 70), Hb E‐β‐thalassemia (n = 25), homozygous β‐thalassemia (n = 4), heterozygous δβ0‐thalassemia (n = 2), and carriers of the β‐Hb variant (n = 3). Mutation analysis identified in addition to the Hb E, 8 different β‐thalassemia mutations including codon 17 (A‐T), codons 41/42 (‐TTCT), NT‐28 (A‐G), codons 71/72 (+A), IVS1‐1 (G‐T), 3.4 kb deletion, an initiation codon (T‐G) and IVS2‐654 (C‐T). Two δβ0‐thalassemia carriers (12.6 kb deletion) and three subjects with Hb Hope (β136GGT‐GAT) were identified. Hematological features associated with these β‐hemoglobinopathies were presented. Conclusion β‐hemoglobinopathies in the Laos population is heterogeneous. This information is relevant for setting up a molecular diagnostics and can provide a basis for genetic counseling and enable prenatal diagnosis.

IntroductionChildren requiring multiple blood transfusions are at high risk of transfusion-transmissible infections (TTIs). Lao People’s Democratic Republic is a low-resource setting where donor blood screening faces challenges. This study aimed to determine the burden of TTIs in children in Vientiane Capital.Methods300 children with transfusion history and 300 controls were recruited. In addition, 49 newly diagnosed transfusion recipients were followed for up to 12 months. Serum was tested for hepatitis B surface antigen and IgG antibodies against parvovirus B19, hepatitis B, C and E viruses.ResultsThe patients had a similar prevalence of anti-hepatitis B core antibodies (56; 18.7%) and hepatitis B surface antigen (8; 2.7%) as the controls (58; 19.3% and 9; 3.0%, respectively). However, there was a higher prevalence of an antibody profile suggestive of hepatitis B vaccination (anti-hepatitis B surface antibody positive/anti-hepatitis B core antibody negative) in the transfused group (140/299; 46.8%) than in controls (77/300; 25.7%, p<0.01). All other markers were similar in the patients and controls or higher in the controls: anti-hepatitis C virus (2.7% and 3.3%, p=0.6), anti-hepatitis E virus (7.5% and 12.7%, p=0.006) and anti-parvovirus B19 (2.4% and 8.5%, p=0.001). The longitudinal cohort did not show an increase in any marker over time.ConclusionOur results suggest no significant role of TTIs in Lao children. The higher prevalence of the hepatitis B vaccination profile in transfusion recipients showed that recommendations to vaccinate before commencing transfusions is at least partially implemented, although there is room for improvement.